Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma
NCT ID: NCT05935332
Last Updated: 2024-07-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
38 participants
INTERVENTIONAL
2023-07-05
2024-06-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderate Asthma
NCT01591044
Efficacy of Symbicort pMDI Administered Once Daily in Adolescents and Adults During 12 Weeks - STEM
NCT00652392
Safety, Tolerability, and Pharcodynamics of AMG 853 in Adolescents With Asthma
NCT01137565
AMG 853 Phase 2 Study in Subjects With Inadequately Controlled Asthma
NCT01018550
A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma
NCT06637371
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
After a screening period subjects will receive standardized, inhaled therapy during a run-in period. Subjects will be randomized to receive RPT193 or placebo through Week 14. All enrolled subjects will receive background inhaled therapy with ICS and LABA.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
RPT193 400 mg
RPT193
RPT193 is an antagonist of the C-C motif chemokine receptor 4 (CCR4) that inhibits CCR4-mediated chemotaxis toward both CCL22 and CCL17
Placebo
Placebo
placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RPT193
RPT193 is an antagonist of the C-C motif chemokine receptor 4 (CCR4) that inhibits CCR4-mediated chemotaxis toward both CCL22 and CCL17
Placebo
placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Pre-bronchodilator FEV1 of \>40% and \<80%
* History of treatment with corticosteroid or hospitalization for worsening asthma
* Medium- or high-dose inhaled corticosteroid use
Exclusion Criteria
* History of severe COVID
* Serious and/or uncontrolled pulmonary, cardiac, immune system conditions
* Requires systemic oral or IV corticosteroids in the month prior to screening
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
RAPT Therapeutics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Laurence Cheng, MD, PhD
Role: STUDY_DIRECTOR
RAPT Therapeutics, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Allergy and Asthma Associates of Santa Clara Valley Research Center
San Jose, California, United States
Bensch Clinical Research LLC
Stockton, California, United States
Allianz Research Institute
Westminster, California, United States
Allianz Research Institute CO
Aurora, Colorado, United States
Sonce Medical Research
Miami, Florida, United States
Coral Research Clinical Corp
Miami, Florida, United States
San Marcos Research Clinic
Miami Lakes, Florida, United States
Clinical Research Trials of Florida
Tampa, Florida, United States
OK Clinical Research LLC
Edmond, Oklahoma, United States
Velocity Clinical Research Grants Pass
Grants Pass, Oregon, United States
Western Sky Medical Research
El Paso, Texas, United States
Metroplex Pulmonary & Sleep Center
McKinney, Texas, United States
Allergy, Asthma & Sinus Ceneter SC
Greenfield, Wisconsin, United States
Medical Center "Zadrave-1"
Kozloduy, , Bulgaria
Medical Center Excelsior
Sofia, , Bulgaria
Diagnostic-Consultative Center Convex Ltd.
Sofia, , Bulgaria
University Multiprofile Hospital for Active Treatment
Stara Zagora, , Bulgaria
Medical Center "ResearchExpert" Ltd
Varna, , Bulgaria
Specialized Hospital for Active Treatment of Pneumo-Phthisiatric Diseases - Vratsa
Vratsa, , Bulgaria
MediTrial s.r.o
Jindřichův Hradec, , Czechia
Trialmed Sp z. o.o.o CRS Warszawa
Warsaw, Solipska, Poland
Centrum Medycyny Oddechowej Mróz Spółka Jawna
Bialystok, , Poland
NZOZ Poradnie Specjalistyczne Atopia
Krakow, , Poland
IP Clinic Sp. z.o.o
Lodz, , Poland
Centrum Diagnostyczno Terapeutyczne MEDICUS Sp. z o.o. - Szpital
Lubin, , Poland
Trialmed CRS (Piotrków Trybunalski)
Piotrkow Trybunalski, , Poland
Specjalistyczna Przychodnia Lekarska Alergo-Med sp. z o.o
Poznan, , Poland
Michal Bogacki - Dobrostan
Wroclaw, , Poland
Lekarze Specjaliści - J. Małolepszy i Partnerzy
Wroclaw, , Poland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RPT193-03
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.